Publications by authors named "Alberto Molero"
This real-world study aimed to describe patient and clinical characteristics, treatment patterns and outcomes for patients with HR+/HER2- metastatic breast cancer receiving abemaciclib in France, Italy and Spain. A multicenter chart review was conducted for adult females with HR+/HER2- advanced/metastatic breast cancer who received abemaciclib in routine care. Real-world progression-free survival (rwPFS) was estimated via Kaplan-Meier curves.
View Article and Find Full Text PDFIntroduction/objectives: To describe abemaciclib use in patients with hormone receptor-positive, human epidermal growth factor receptor-negative (HR+/HER2-) metastatic breast cancer (mBC) who participated in the Named Patient Use program (NPU) in Spain.
Material And Methods: This retrospective study was based on medical record review of patients across 20 centers during 2018/2019. Patients were followed up until death, enrolment in a clinical trial, loss of follow-up or study end.
Article Synopsis
- This study analyzes the burden of inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), in Spain through systematic reviews of relevant studies from 2011 to 2021.
- The findings indicate that the incidence of IBD in adults ranges significantly and has doubled since 2000, with key symptoms differing between CD and UC, and a notable occurrence of psychiatric comorbidities.
- The impact of IBD on health-related quality of life (HRQoL) is substantial, resulting in high healthcare resource utilization and significant annual costs for patients.
Article Synopsis
- A retrospective study was conducted across 20 hospitals in Spain to analyze the use and effectiveness of ramucirumab in treating advanced gastric cancer (AGC) and gastroesophageal junction adenocarcinoma (GEJ) in patients between December 2015 and December 2018.
- The study included 317 patients, with the majority receiving a combination treatment of ramucirumab and paclitaxel; most patients were around 62.5 years old and predominantly male.
- Results showed that the median progression-free survival was 3.9 months for combination therapy and 2.0 months for monotherapy, while overall survival was 7.4 months and 4.3 months, respectively, aligning with existing